Myrbetriq

(Mirabegron)

Myrbetriq

Drug updated on 11/9/2023

Dosage FormTablet (oral; 25 mg, 50 mg); Granules (oral; 8 mg/mL)
Drug ClassBeta-3 adrenergic agonists
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Myrbetriq tablet is indicated for the treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and urinary frequency either alone or in combination with the muscarinic antagonist solifenacin succinate.
  • Myrbetriq tablet is indicated for the treatment of neurogenic detrusor overactivity (NDO) in patients aged 3 years and older who weigh 35 kg or more.
  • Myrbetriq granules is indicated for the treatment of neurogenic detrusor overactivity (NDO) in patients aged 3 years and older.

Product Monograph / Prescribing Information

Document TitleYearSource
Myrbetriq (mirabegron) Prescribing Information2021Astellas Pharma US Inc., Northbrook, IL

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Comparative assessment of efficacy and safety of approved oral therapies for overactive bladder: a systematic review and network meta-analysis. 2023International Brazilian Journal of Urology
Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis. 2023Revista Brasileira de Ginecologia e Obstetrícia
Efficacy and safety of vibegron compared with mirabegron for overactive bladder: A systematic review and network meta-analysis. 2023Lower Urinary tract symptoms
Urodynamic parameter improvements after mirabegron vs. antimuscarinics agents in non-neurogenic overactive bladder: a systematic review and meta-analysis of treatment effect. 2023European review for medical and pharmacological sciences
Comparison of different types of therapy for overactive bladder: a systematic review and network meta-analysis.2022Frontiers in Medicine
Efficacy and safety of mirabegron for treatment of neurogenic detrusor overactivity in adults with spinal cord injury or multiple sclerosis: a systematic review.2022Spinal Cord
Cost-effectiveness evaluation of mirabegron versus anti-muscarinics and third-line therapies: a systematic review. 2022Expert Review of Pharmacoeconomics & Outcomes Research
Long-term efficacy and safety of vibegron versus mirabegron and anticholinergics for overactive bladder: a systematic review and network meta-analysis. 2022Drugs in context
Efficacy of overactive neurogenic bladder treatment: A systematic review of randomized controlled trials. 2022Archives of Italian urology and andrology
Beta 3 adrenoreceptor agonist for the management of lower urinary tract symptoms in men with benign prostatic hyperplasia: a systematic review.2021International Neurology Journal
Monotherapy with mirabegron had a better tolerance than the anticholinergic agents on overactive bladder: a systematic review and meta-analysis.2021Medicine
The efficacy and safety of mirabegron in treating ureteral stent-related symptoms: a systematic review and meta-analysis.2021Lower Urinary Tract Symptoms
Efficacy of vibegron and mirabegron for overactive bladder: a systematic literature review and indirect treatment comparison.2021Advances in Therapy
Mirabegron for the treatment of ureteral stent-related symptoms: a systematic review and meta-analysis.2021European Urology Focus
The use of mirabegron in neurogenic bladder: a systematic review.2020World Journal of Urology
Comparative safety and efficacy of treatments for overactive bladder among older adults: a network meta‚ÄĎanalysis.2020Drugs and Aging
The relative efficacy and safety of mirabegron and onabotulinumtoxinA in patients with overactive bladder who have previously been managed with an antimuscarinic: a network meta-analysis.2019Urology
Updating the evidence on drugs to treat overactive bladder: a systematic review.2019International Urogynecology Journal
Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis.2018European Urology
Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review.2018BMJ Open
Systematic review of combination drug therapy for non-neurogenic lower urinary tract symptoms.2018European Urology

Clinical Practice Guidelines